Healthcare Holding B.V. Gilde Sells 7,338 Shares of Shoulder Innovations (NYSE:SI) Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $22.64, for a total transaction of $166,132.32. Following the transaction, the insider directly owned 2,214,302 shares in the company, valued at $50,131,797.28. This represents a 0.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total transaction of $47,347.00.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total transaction of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.71, for a total transaction of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Price Performance

Shares of Shoulder Innovations stock opened at $20.54 on Friday. The stock’s 50-day simple moving average is $19.91 and its 200-day simple moving average is $16.07. Shoulder Innovations, Inc. has a 52 week low of $10.92 and a 52 week high of $24.59. The company has a market capitalization of $426.06 million and a price-to-earnings ratio of -10.70. The company has a quick ratio of 10.04, a current ratio of 11.81 and a debt-to-equity ratio of 0.11.

Shoulder Innovations (NYSE:SI) last released its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.03. The firm had revenue of $16.71 million during the quarter. Shoulder Innovations had a negative return on equity of 22.93% and a negative net margin of 58.33%. As a group, analysts expect that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current fiscal year.

More Shoulder Innovations News

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Hedge Funds Weigh In On Shoulder Innovations

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. bought a new position in Shoulder Innovations during the third quarter valued at $6,056,000. Alyeska Investment Group L.P. bought a new stake in shares of Shoulder Innovations in the 3rd quarter worth about $5,667,000. Vanguard Group Inc. bought a new stake in shares of Shoulder Innovations in the 3rd quarter worth about $1,836,000. Roubaix Capital LLC raised its position in shares of Shoulder Innovations by 61.9% during the 1st quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock valued at $3,736,000 after buying an additional 98,305 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Shoulder Innovations in the 4th quarter valued at about $1,316,000.

Wall Street Analyst Weigh In

SI has been the subject of a number of research analyst reports. BTIG Research increased their price objective on shares of Shoulder Innovations from $24.00 to $26.00 and gave the company a “buy” rating in a report on Friday. Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a research report on Friday. UBS Group began coverage on shares of Shoulder Innovations in a research note on Tuesday, July 28th. They set a “buy” rating and a $27.00 target price for the company. Finally, Weiss Ratings upgraded shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.